0001104659-21-134772.txt : 20211105 0001104659-21-134772.hdr.sgml : 20211105 20211105084904 ACCESSION NUMBER: 0001104659-21-134772 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211102 FILED AS OF DATE: 20211105 DATE AS OF CHANGE: 20211105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PARMAR KUSH CENTRAL INDEX KEY: 0001664281 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40969 FILM NUMBER: 211382467 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entrada Therapeutics, Inc. CENTRAL INDEX KEY: 0001689375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813983399 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6 TIDE STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: 6 TIDE STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: CycloPorters, Inc. DATE OF NAME CHANGE: 20161104 4 1 tm2132054-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-11-02 0 0001689375 Entrada Therapeutics, Inc. TRDA 0001664281 PARMAR KUSH C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET BOSTON MA 02210 1 0 1 0 Common Stock 2021-11-02 4 C 0 318616 A 649771 I See Footnote Common Stock 2021-11-02 4 C 0 2371739 A 3021510 I See Footnote Common Stock 2021-11-02 4 C 0 564217 A 564217 I See Footnote Common Stock 2021-11-02 4 C 0 254512 A 3276022 I See Footnote Common Stock 2021-11-02 4 C 0 318140 A 882357 I See Footnote Common Stock 2021-11-02 4 P 0 250000 20 A 1132357 I See Footnote Series Seed Preferred Stock 2021-11-02 4 C 0 318616 0 D Common Stock 318616 0 I See Footnote Series A Preferred Stock 2021-11-02 4 C 0 2371739 0 D Common Stock 2371739 0 I See Footnote Series A Preferred Stock 2021-11-02 4 C 0 564217 0 D Common Stock 564217 0 I See Footnote Series B Preferred Stock 2021-11-02 4 C 0 254512 0 D Common Stock 254512 0 I See Footnote Series B Preferred Stock 2021-11-02 4 C 0 318140 0 D Common Stock 318140 0 I See Footnote Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein. On November 2, 2021, Opportunities purchased 250,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. /s/ Jared Cohen, as Attorney-in-Fact 2021-11-05